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Abstract
Introduction: The risk of developing insulin resistance and metabolic syndrome is particularly high in central obesity. In this study we 
evaluated the effects of fat distribution and some adipokines on insulin resistance in prediabetic patients.
Material and methods: Eighty-seven age- and sex-matched patients were divided into three groups according to their 75-gram oral 
glucose tolerance test results as follows: impaired fasting glucose group, impaired glucose tolerance group, and normal glucose tolerance 
group. Fasting insulin levels were measured. Homeostatic model assessment of insulin resistance was calculated. Body fat mass meas-
urements were assessed by bioelectric impedance analyser and abdominal fat thicknesses (subcutaneous, visceral, and preperitoneal) by 
ultrasonography. The fasting serum levels of several adipokines [adiponectin, leptin, resistin, vaspin, visfatin, retinol-binding protein-4 
(RBP-4), tumour necrosis factor-a (TNF-a)] were measured by ELISA method.
Results: The mean body mass index, fat mass measurements, and abdominal fat thicknesses of the groups were similar. There were no dif-
ferences between groups in terms of the mean fasting insulin, vaspin, RBP-4, leptin, resistin, and TNF-a. In comparison of the prediabetic 
and normal groups, the levels of adiponectin (p < 0.001) and visfatin (p < 0.001) were lower in the prediabetic group. Furthermore, we 
found that high body mass index (p < 0.01) and fat mass (p < 0.01) and low adiponectin (p < 0.05) levels have roles in the development 
of insulin resistance in the prediabetic group.
Conclusions: We suggested that in the prediabetic period not only obesity but also decreased adiponectin levels play some role in the 
pathogenesis of insulin resistance. (Endokrynol Pol 2016; 67 (3): 277–282)
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Streszczenie
Wstęp: Ryzyko rozwoju insulinooporności i zespołu metabolicznego zwiększa się zwłaszcza u osób z otyłością centralną. W niniejszym 
badaniu oceniono wpływ dystrybucji tkanki tłuszczowej i wybranych adipokin na insulinooporność u osób ze stanem przedcukrzycowym.
Materiał i metody: Osiemdziesięciu siedmiu chorych dobranych pod względem wieku I płci podzielono na 3 grupy w zależności od 
wyniku testu doustnego obciążenia 75 g glukozy: osoby z nieprawidłową glikemią na czczo, osoby z nieprawidłową tolerancją glukozy 
i osoby z prawidłową tolerancją glukozy. Zmierzono stężenie insulin na czczo. Do oszacowania insulinooporności zastosowano model 
homeostazy. Masę tkanki tłuszczowej oceniono za pomocą analizatora bioimpedancji elektrycznej, a grubość brzusznej tkanki tłuszczo-
wej (podskórnej, trzewnej i przedotrzewnowej) zmierzono metodą ultrasonograficzną. Stężenie na czczo w surowicy kilku adipokin 
(adiponektyna, leptyna, rezystyna, waspina, wisfatyna, białko wiążące retinol-4 [RBP-4], czynnik martwicy nowotworów a [TNF-a]) 
zmierzono, stosując metodę ELISA.
Wyniki: Średni wskaźnik masy ciała, masa tkanki tłuszczowej I grubość brzusznej tkanki tłuszczowej były podobne we wszystkich gru-
pach. Nie stwierdzono różnic między grupami pod względem średniego stężenia insuliny na czczo ani stężeń waspiny, RBP-4, leptyny, 
rezystyny i TNF-a. W porównaniu grup ze stanem cukrzycowym i grupy z prawidłową tolerancją glukozy wykazano, że stężenia adipo-
nektyny (p < 0,001) i wisfatyny (p < 0,001) były niższe u osób ze stanem przedcukrzycowym. Ponadto stwierdzono, że wysoki wskaźnik 
masy ciała (p < 0,01) i duża masa tkanki tłuszczowej (p < 0,01) oraz niskie stężenie adiponektyny (p < 0,05) przyczyniają się do rozwoju 
insulinooporności u osób ze stanem przedcukrzycowym.
Wnioski: Autorzy sugerują, że nie tylko otyłość, ale również obniżenie stężenia adiponektyny odgrywają pewną rolę w patogenezie 
insulinooporności w okresie przedcukrzycowym. (Endokrynol Pol 2016; 67 (3): 277–282)
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Introduction
It is well known that obesity is an important risk factor 
for the development of insulin resistance (IR), diabetes 
mellitus (DM), and cardiovascular diseases. The patho-
physiological relationship between obesity and IR is 
based on not only the degree of obesity but also on the 
distribution of the fat tissue.
Adipose tissue is a multi-factorial endocrine or-
gan secreting some paracrine and endocrine factors 
known as adipokines. While some of these adipokines 
play an important role in the development and pro-
gression of IR, such as tumour necrosis factor-a and 
resistin, some others improve insulin sensitivity, such 
as adiponectin. 
The prediabetic stage comprises impaired fasting 
glucose (IFG) and impaired glucose tolerance (IGT) 
terms [1]. The importance of prediabetes comes from 
the fact that subjects with prediabetes have an increased 
risk of developing overt Type 2 DM.
We aimed to evaluate the serum levels of some adi-
pokines, body fat distribution, and their relationship 
with IR in prediabetic subjects.
Material and methods
Subjects
In total 87 subjects were included in this study. The 
subjects who were under treatment with any drugs 
affecting glucose metabolism (metformin, oral contra-
ceptive drugs, beta-blockers, glucocorticoids, etc.) or 
were diagnosed with DM, chronic renal failure, hepatic 
dysfunction, thyroid dysfunction, Cushing’s syndrome, 
any malignancy, or pregnant women were excluded 
from the study. The subjects were divided into three 
groups according to their 75-gram oral glucose toler-
ance test (OGTT) results [1]. 1) IFG group (n = 27); 2) 
IGT group (n = 36); 3) healthy subjects with normal 
glucose metabolism as control group (n = 24). The local 
ethics committee approved the study design and the 
study was performed in accordance with the ethical 
standards as laid down in the 2008 amendment of the 
Declaration of Helsinki. Written informed consent was 
given by each of the participants.
Weight, body fat mass, fat-free lean mass, and total 
fat percentages were determined in subjects using 
a foot-to-foot bioelectric impedance analyser TBF-300 
TANITA (Germany) digital scale. Height was measured 
by a standard tape measure, and body mass index (BMI) 
was calculated as kg/m2. Waist circumference was meas-
ured by a standard tape measure after expirium as the 
widest circumference at the level of the right anterior 
superior iliac spine, parallel to the floor.
Blood Sampling and Assay Methods
OGTT was done with 75-gram standard anhydrous glu-
cose. The glucose was ingested in 300 ml of water after 
overnight fasting. Blood samples were drawn initially 
and two hours after ingestion. Plasma fasting glucose, 
serum total cholesterol, high density lipoprotein-cho-
lesterol (HDL-C), low density lipoprotein-cholesterol 
(LDL-C), and triglyceride levels were determined by 
spectrophotometry method (Advia 1800 Clinical 
Chemistry System Siemens, USA). The fasting serum 
insulin levels were assessed by chemiluminescence 
method (Beckman-Coulter Inc., USA). Homeostatic 
model assessment of IR (HOMA-IR) was calculated by 
the formula: 
glucose [mg/dL] × insulin [m IU/mL]/405.
After centrifugation, blood samples were stored at 
— 85°C until analysis. The fasting serum levels of the 
adiponectin, retinol-binding protein 4 (RBP-4), tumour 
necrosis factor-a (TNF-a), leptin, resistin (AssayMax, 
Assaypro, USA), vaspin, and visfatin (RayBiotech Inc., 
USA) were determined by ELISA method.
Ultrasonography
Abdominal fat distributions were assessed by the same 
radiologist with a Esaote S.P.A-Italia MyLab 60 ultra-
sonography machine while the patient was holding 
his/her breath. Subcutaneous fat (SF) thickness was 
assessed by 12-MHz linear probe, and visceral fat (VF) 
and preperitoneal fat (PF) thicknesses were assessed by 
5-MHz convex probe.
Statistical analyses
All statistical analyses were performed using SPSS 17.0 
software for Windows. The normality of the distribu-
tion of all variables was assessed by the Kolmogorov-
Smirnov test. The comparisons between groups were 
analyzed by c2, ANOVA and Kruskal-Wallis test. Pear-
son’s and Spearman’s rank correlation coefficients were 
used to quantify the relations between the variables. 
P < 0.05 was regarded as statistically significant.
Results
The demographic, anthropometric, and laboratory data of 
all groups are shown in Table I and II. There were no sta-
tistically significant differences between groups in terms 
of age, gender, BMI, the mean levels of total fat mass, total 
fat percentages, and fat thicknesses (SF, VF, PF). 
The mean levels of waist circumference and HOMA-
IR in the IGT group were significantly higher than 
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in the control group (p < 0.05, p < 0.05) whereas no 
significant differences were detected in serum insulin 
and lipid parameters among groups. When the groups 
were compared statistically, no difference was observed 
in the serum levels of adipokines, except adiponectin 
and visfatin. Mean adiponectin and visfatin levels of 
both IFG and IGT groups were lower than the control 
group (p: for adiponectin < 0.001 and < 0.01; for visfatin 
< 0.05 and < 0.001, respectively), but no difference was 
found between the IFG and IGT groups. In the predia-
betic group there were positive correlations between 
HOMA-IR and BMI (p < 0.01), waist circumference 
(p < 0.05), second hour glucose level in OGTT (p < 0.05), 
body fat percentage (p < 0.05), total fat mass (p < 0.01), 
and visceral fat thickness (p = 0.01). In contrast, there 
was a negative correlation between HOMA-IR and 
adiponectin levels (p < 0.05) (Table III).
Discussion
Prediabetes is a state indicating a relatively high risk for 
future development of DM [1]. In a study examining 
the prevalence of prediabetes and diabetes in a Turkish 
adult population, the crude prevalence of prediabetes 
was 30.8% (isolated-IFG 14.7%, isolated-IGT 7.9%, and 
combined 8.2%) [2]. In isolated IFG, hepatic IR and insuf-
ficiently suppressed endogenous glucose production are 
the main pathophysiological phenomena; however, in 
isolated IGT increased peripheral IR and decreased total 
body glucose disposal are the main problems.
Adipokines are a cytokine group that are released 
from adipocytes. Studies to uncover their roles on IR 
pathogenesis give conflicting results. In this study, we 
aimed to evaluate the effects of some adipokines and 
body fat distribution on IR in prediabetic patients.
Table I. The anthropometric measurements, biochemical and ultrasonographic results of the groups
Tabela I. Wyniki pomiarów antropometrycznych, biochemicznych i ultrasonograficznych w poszczególnych grupach
IFG group (n = 27) IGT group (n = 36) Control group (n = 24)
Gender (F/M) 14/13 26/10 16/8
Age (year) 49 ± 12.73 51.7 ± 13.1 44.4 ± 10.3
BMI [kg/m2] 27.7 ± 4.1 29.7 ± 3.5 27.4 ± 5
Waist circumference [cm] 100.8 ± 9.5 104.3 ± 8.1a 97.8 ± 12
Fasting glucose [mmol/L] 6.0 ± 0.3b 5.8 ± 0.5c 4.9 ± 0.3
OGTT 2nd hour glucose [mmol/L] 6.2 ± 1.2d 8.8± 0.8c 5.53 ± 1.39
Fasting serum insulin [pmol/L] 59.7 ± 26.3 77 ± 40.9 57.6 ± 43.7
HOMA-IR 2.33 ± 1.1 2.85 ± 1.4a 1.85 ± 1.4
Total cholesterol [mmol/L] 5.0 ± 0.8 5.2 ± 0.8 5.4 ± 1.2
HDL-C [mmol/L] 1.1 ± 0.3 1.1 ± 0.2 1.3 ± 0.3
LDL-C [mmol/L] 3.2 ± 0.7 3.4 ± 0.8 3.6 ± 1.1
Triglyceride [mmol/L] 1.4 ± 0.8 1.8 ± 1.5 1.4 ± 0.6
Adiponectin [µg/mL] 8.5 ± 5.8b 12.1 ± 8.8e 25.7 ± 22.4
Vaspin [ng/mL] 154.3 ± 640.5 33.3 ± 115.8 61.7 ± 176.3
Visfatin [ng/mL] 886 ± 95f 847 ± 96c 946 ± 68
RBP-4 [ng/mL] 37.03 ± 6.8 34.3 ± 7.04 39.01 ± 7.97
Leptin [ng/mL] 2.5 ± 1.6 3.2 ± 2.9 5.8 ± 9.7
Resistin [ng/mL] 2.4 ± 0.9 2.8 ± 1.6 3.2 ± 1.5
TNF-a [ng/mL] 0.028 ± 0.017 0.024 ± 0.016 0.023 ± 0.004
Total fat (%) 29.3 ± 7.9 34 ± 6.6 29.4 ± 9.5
Total fat mass [kg] 22 ± 7.6 26.3 ± 6.7 22.3 ± 9.2
Subcutaneous fat thickness[mm] 17.3 ± 5.5 18.4 ± 6.2 17.7 ± 5.8
Visceral fat thickness [mm] 47.6 ± 18.3 57.6 ± 24.9 46.1 ± 21.2
Preperitoneal fat thickness [mm] 14 ± 9.2 14.5 ± 8.3 12.7 ± 5.7
aIGT group vs. control group, p < 0.05; bIFG group vs. control group, p < 0.001; cIGT group vs. control group, p < 0.001; dIFG group and IGT group, p < 0.001;  
eIGT group vs. control groups, p < 0.01; fIFG group and control group, p < 0.05
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As expected, the IR of our prediabetic patients was 
higher than that of the control group. Our data indi-
cated that IR increased in parallel to the waist circum-
ferences from the normal glucose tolerance group to 
IFG and then to IGT groups. The fact that abdominal 
obesity has a positive correlation with the IR has been 
known for a long time. So the result obtained in our 
study is consistent with earlier findings [3].
It is known that metabolic problems are more 
prevalent in patients with increased visceral fat mass. 
Furthermore, visceral fat tissue is an important source 
of adipokines predominantly increasing IR.
In our study, we did not find any difference between 
prediabetic patients and normal glucose metabolism 
group in terms of BMI, fat percentages and fat distribu-
tions. This result might be due to our small study cohort.
In our study we suggested that decreased adiponec-
tin levels might have some role in the early stages of 
impaired glucose metabolism. Furthermore, we found 
that in the prediabetic stage, decrements in adiponectin 
levels and increments in fat mass, especially the visceral 
Table II. The anthropometric measurements, biochemical and ultrasonographic results of the prediabetes group as a whole 
and the control group
Tabela II. Wyniki pomiarów antropometrycznych, biochemicznych i ultrasonograficznych w połączonej grupie obejmującej 
wszystkie osoby ze stanem przedcukrzycowym i w grupie kontrolnej
Prediabetes group (n = 63) Control group (n = 24) P
Gender (F/M) 40/23 16/8 Ns*
Age (year) 50.6 ± 12.9 44.4 ± 10.3 Ns
BMI [kg/m2] 28.8 ± 3.9 27.4 ± 5 Ns
Waist circumference [cm] 102.8 ± 8.8 97.8 ± 12.5 Ns
Fasting glucose [mmol/L] 5.9 ± 0.5 4.9 ± 0.3  < 0.001
OGTT 2ndhour glucose [mmol/L] 7.7 ± 1.6 5.5 ± 1.3  < 0.001
Fasting serum insulin [pmol/L] 70.1 ± 36.1 57.6 ± 43.7 Ns
HOMA-IR 2.63 ± 1.35 1.85 ± 1.41  < 0.05
Total cholesterol [mmol/L] 5.2 ± 0.8 5.4 ± 1.2 Ns
HDL-C [mmol/L] 1.1 ± 0.2 1.3 ± 0.3 Ns
LDL-C [mmol/L] 3.3± 0.7 3.6 ± 1.1 Ns
Triglyceride [mmol/L] 1.6 ± 1.3 1.4 ± 0.6 Ns
Adiponectin [µg/mL] 10.6 ± 7.8 25.7 ± 22.4  < 0.001
Vaspin [ng/mL] 86.6 ± 433.5 61.7 ± 176.3 Ns
Visfatin [ng/mL] 864 ± 96 946 ± 68  < 0.001
RBP-4 [ng/mL] 35.57 ± 7.0 39.01 ± 7.97 Ns
Leptin [ng/mL] 2.97 ± 2.52 5.8 ± 9.7 Ns
Resistin [ng/mL] 2.6 ± 1.3 3.2 ± 1.5 Ns
TNF-a [ng/mL] 0.026 ± 0.016 0.023 ± 0.004 Ns
Total fat (%) 32 ± 7.5 29.4 ± 9.5 Ns
Total fat mass [kg] 24.5 ± 7.4 22.3 ± 9.2 Ns
Subcutaneous fat thickness[mm] 17.9 ± 5.9 17.7 ± 5.8 Ns
Visceral fat thickness [mm] 53.3± 22.7 46.1 ± 21.2 Ns
Preperitoneal fat thickness [mm] 14.3 ± 8.6 12.7 ± 5.7 Ns
Table III. The associations between clinical parameters and 
HOMA-IR in patients with prediabetes
Tabela III. Zależności między parametrami klinicznymi 
a wskaźnikiem HOMA-IR u osób ze stanem przedcukrzycowym
r P
Body mass index [kg/m2] 0.367  < 0.01
Waist circumference [cm] 0.361  < 0.05
OGTT 2nd hour glucose [mg/dL] 0.282  < 0.05
Total fat percentage (%) 0.308  < 0.05
Total fat mass [kg] 0.411  < 0.01
Visceral fat thickness [cm] 0.395  0.01
Adiponectin [µg/mL] –0.322  < 0.05
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one, have some role in the development of IR, which 
has a major role in DM pathogenesis.
In the follow-up of 341 women, those with incident 
diabetes had lower basal serum adiponectin levels in 
the normal glucose tolerance, IFG, and IGT stages 
compared to those who did not develop DM during 
5.5 years of follow-up [4]. As a result, low adiponectin 
level was concluded as a predictor of future diabetes 
and an indicator of the IR. In our study adiponectin 
levels were also lower in the insulin resistant groups.
Visfatin was first introduced by Fukuhara et al. in 
their mice and human cell culture study [5] as a novel 
insulinomimetic adipokine. But recently visfatin was 
shown as a proinflammatory adipokine causing sys-
temic IR and dyslipidaemia [6]. So the role of visfatin in 
human pathophysiology is pending clearance because 
many of the studies on the effects of visfatin are not in 
accordance with each other [7, 8].
There are significant differences in immunoassays 
of visfatin in regard to the treatment and type of sam-
ples. Freeze–thaw cycles and different sample additives 
have considerable influence on the measurement of 
visfatin concentrations [9]. Also, Körner et al. revealed 
the difference between some commercially available 
immunoassays in terms of specificity and sensitivity 
of visfatin detection in human serum and plasma [10]. 
Our study results showed that visfatin levels were lower 
in the prediabetic group than in the control group and 
visfatin was inversely proportional to IR. In a recent 
study, visfatin levels in obese patients with glucose 
metabolism disorders were found to be lower than 
obese patients without glucose metabolism disorders, 
but they did not reach statistical significance (as our 
study results did) [11]. On the other hand, our results 
are incompatible with the meta-analysis reported by 
Chang et al. [8]. This difference in the results might be 
due to our small sample size or the qualitative/quantita-
tive detection differences of visfatin by immunoassays.
Resistin is also a controversial adipokine in terms 
of IR. Overexpression of resistin in human hepatocytes 
induced IR by blocking two insulin signal transduction 
pathways of PI-3K/Akt and of CAP/c-cbl [12]. In a study 
comparing plasma resistin levels of lean-insulin sensi-
tive, lean-insulin resistant, and obese-insulin resistant 
cases, any statistically significant differences between 
groups or correlation of resistin to insulin sensitivity 
and intra-abdominal fat tissue were not found [13]. In 
the present study, also, we did not find any difference 
between groups with different insulin sensitivity status. 
There are also controversial results regarding the 
RBP4-IR relationship. In the study of Cho et al. [14] 
RBP4 levels of normal glucose-tolerant subjects were 
found to be significantly lower than IGT and type 2 
diabetic patients. In another study [15] RBP4 levels 
when corrected with regard to age and gender were 
not found to be in association with IR in obese patients. 
As in the previously mentioned study, in our study no 
difference was found between groups in terms of RBP4 
levels. Some factors might be effective in this result. It is 
known that serum RBP4 levels are affected by plasma 
transthyretin and retinol levels, but we were not able 
to measure these levels due to financial limitations. 
Furthermore, the gold standard method of RBP4 meas-
urement is quantitative western blotting [16], but in our 
study ELISA was used. This result might be caused by 
this methodological difference.
The correlation of leptin levels with IR has been 
studied in many reports [17–19]. In some of them leptin 
levels were positively related with IR [17–18], but in oth-
ers no statistical significances were reached [19]. In the 
present study, we did not reach any difference in leptin 
levels between groups. Wauters et al. [20] supposed that 
the main determinants for leptin levels in diabetics and 
healthy subjects were fat mass and gender. In our study, 
there were no differences between groups in terms of 
gender and fat mass parameters. So the indifference 
in leptin levels between groups might be due to the 
indifferences in these main determinants or it might 
be due to our small sample size.
In our study, serum TNF-a concentrations were 
extremely low and were not statistically different be-
tween groups. It was also not correlated with HOMA-IR 
values, as in the results of Bruun et al. [21]. It is known 
that TNF-a acts as an autocrine-paracrine basis, not 
an endocrine basis. So, the indifference between the 
groups might be related to the measurement of TNF-a 
in the serum, not at the tissue level, which is the real 
indicator of its effect on the IR.
von Loeffelholz et al. [22] found no correlation 
of HOMA-IR with circulating vaspin in non-diabetic 
cases. Our study was in accordance with this finding 
also by the lack of correlation between HOMA-IR and 
vaspin levels.
In the current study, the parameter with the strong-
est correlation with HOMA-IR was found to be visceral 
fat thickness. This result supports the well-known fact 
that visceral fat tissue is a powerful factor responsible 
for IR and even the development of type 2 DM [23].
There are some limitations of the present study, 
which might affect our results. Due to its easiness and 
low cost, in the measurement of IR we used HOMA-IR 
instead of the gold standard technique — hyperinsuli-
naemic-euglycaemic clamp test. So some limitations to 
the study may be borne from this method difference. 
Moreover, standardisation of the ultrasonographic 
measurements is very difficult due to the lack of a com-
mon probe localisation point for fat thicknesses, vari-
ability during respiratory cycles, and low probability of 
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reproducibility. Because of ethical issues regarding the 
radiation exposure during computerised tomography 
imaging and easiness and low cost of US, although CT 
is more sensitive than US for the measurement of ab-
dominal fat thicknesses, we used US. So the power of 
the relationship between fat thicknesses and HOMA-IR 
may decrease due to this methodological difference.
The fact that serum levels of the adipokines may 
not always reflect their exact tissue levels might be re-
sponsible for the lack of correlation between HOMA-IR 
and some adipokines in our study. Consequently, if we 
could take fat tissue biopsies for the measurement of 
adipokines instead of their serum levels, the correlation 
of adipokines with IR could be different.
Our study cohort is very small due to our financial 
limitations. If this study were based on a wider popula-
tion, the results of the study might have been different 
from the present issues.
Conclusions
In conclusion, our results support the role of visceral 
adiposity on IR. We suggest that lifestyle modifications 
to minimise abdominal adiposity must begin with the 
diagnosis of prediabetes to slow the progression rate 
to overt diabetes mellitus.
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